Bristol-myers Squibb Compnay

Innate Tumor Immunity, Inc.

Birstol-myers Squibb Company

Hua Gong

Scott Hunter Watterson

Ashvinikumar V Gavai

Christine M Tarby

T G Murali Dhar

Jingwu Duan

Bin Jiang

Shomir Ghosh

William R Roush

Steven P Seitz

Derek J Norris

Yong Zhang

Zhonghui Lu

John E Macor

Ping Chen

Saleem Ahmad

Sing-Yuen Sit

Michael A Poss

Douglas G Batt

Daniel O'Malley

David S Weinstein

Patrice Gill

David K Williams

William John Pitts

Joseph Anthony Tino

Michael G Yang

Yong-Jin Wu

Guanglin Luo

Robert J Cherney

Rajeev S Bhide

Jie Chen

Carolyn Diane Dzierba

Jay A Markwalder

Zili Xiao

Qingjie Liu

Bingwei Vera Yang

Junqing Guo

Khehyong Ngu

Jianliang Shi

Amy C Hart

Brian Lee Venables

Andrew J Tebben

David Marcoux

Zhizhen Barbara Zheng

Zheming Ruan

Lyndon A M Cornelius

Weiwei Guo

Jason M Guernon

Qing Shi

Lan-Ying Qin

Myra Beaudoin Bertrand

Matthias Broekema

Carolyn A Weigelt

Murugaiah Andappan Murugaiah Subbaiah

Arthur M Doweyko

Kristin Williams

Prasanna Sivaprakasam

Lyndon AM Cornelius

TG Murali Dhar

The present invention provides compounds of Formula (I), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

NLRP3 modulators

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of Formula (I), (II) or (III): (I), (II), (III), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human). 

Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, &#x2014;CN, &#x2014;CH, or &#x2014;CF; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R; Qis pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with Rand R; and R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases. 

Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors

Described are ROR&#x3b3; modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders. 

ROR&#x3b3; modulators

Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-B activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification. 

Imide and acylurea derivatives as modulators of the glucocorticoid receptor

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-&#x3ba;B activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

Modulators of glucocorticoid receptor, AP-1, and/or NF-&#x3ba;B activity and use thereof

Growing community of inventors

King of Prussia, PA, United States of America

Hua Gong